Testosterone Patch (Androderm)

Quick Reference Card

Overview / What Is Testosterone Patch (Androderm)?

The Basics

Androderm is a prescription testosterone patch designed to deliver testosterone through your skin continuously over 24 hours. Unlike injections that create peaks and valleys in your testosterone levels, or gels that require careful application and carry the risk of transferring testosterone to others through skin contact, the patch provides a steady, predictable delivery of testosterone that closely mimics your body's natural daily rhythm.

The patch works by a straightforward principle: you apply it to your skin in the evening, and over the next 24 hours, testosterone gradually passes from the patch through your skin and into your bloodstream. Because it is applied at night, the patch replicates the natural pattern where testosterone levels are highest in the early morning and taper through the day. This is a feature unique to the patch among transdermal testosterone products.

Androderm was first approved by the FDA in 1995, making it one of the earlier non-injectable testosterone delivery methods available. It was originally developed as an alternative to the earlier scrotal testosterone patch, providing the same therapeutic benefit without the impracticality of scrotal application. Currently available in 2 mg/day and 4 mg/day strengths, the patch is manufactured by Actavis Pharma (formerly distributed by Allergan). Like all testosterone products in the United States, Androderm is classified as a Schedule III controlled substance and requires a prescription.

It is important to understand that Androderm is specifically approved for men with diagnosed hypogonadism (primary or secondary), not for age-related testosterone decline. The FDA has not established safety and efficacy for "late-onset" or "age-related" hypogonadism, and this distinction matters when discussing treatment options with your healthcare provider.

The Science

Androderm (NDA020489) is a transdermal drug delivery system containing testosterone USP (17-beta-hydroxyandrost-4-en-3-one, C19H28O2, MW 288.42) dissolved in an alcohol-based gel within a central drug reservoir. The system uses a permeation-enhanced design with a microporous polyethylene membrane controlling the rate of testosterone release across the skin [1].

The transdermal delivery approach bypasses hepatic first-pass metabolism, a limitation that historically restricted oral testosterone bioavailability and contributed to hepatotoxicity with 17-alpha-alkylated oral formulations. By delivering unesterified testosterone directly through the stratum corneum, Androderm avoids the need for ester modification required by injectable formulations (cypionate, enanthate, undecanoate) and produces physiological testosterone, DHT, and estradiol ratios [2].

FDA approval was granted on September 29, 1995, based on clinical evidence demonstrating that the non-scrotal transdermal system could achieve physiological testosterone concentrations and mimic the normal circadian variation observed in healthy eugonadal men. This represented a significant advance over earlier scrotal patches, which required application to scrotal skin for adequate absorption and were impractical for many patients [2][3].

Medical / Chemical Identity

System Design:

The Androderm system contains six components:

1. Metallized polyester/Surlyn backing film with alcohol-resistant ink
2. Central drug reservoir: testosterone USP in alcohol, glycerin, glycerol monooleate, methyl laurate, sodium hydroxide, purified water, gelled with carbomer copolymer Type B
3. Permeable polyethylene microporous membrane (rate-limiting)
4. Peripheral acrylic adhesive layer
5. Peelable laminate disc (contains aluminum foil layer)
6. Silicone-coated polyester release liner

Androderm does not contain an ester modification. Unlike injectable testosterone formulations that require ester hydrolysis to release free testosterone, the patch delivers unesterified testosterone directly through the skin. The stratum corneum serves as the depot, with the microporous membrane controlling release rate.

Note: The aluminum foil layer in the disc means the patch must be removed before magnetic resonance imaging (MRI) to prevent skin burns [1].

Mechanism of Action / Pathophysiology

The Basics

When you apply the Androderm patch to your skin in the evening, the testosterone in the patch's central reservoir begins crossing through your outer skin layer and entering the tiny blood vessels beneath. Your skin acts like a controlled gate, allowing testosterone to pass at a steady rate over 24 hours. The alcohol-based gel in the patch helps testosterone move through the skin more effectively than it would on its own.

Once in your bloodstream, the testosterone from the patch works identically to the testosterone your body produces naturally. It travels to tissues throughout your body, entering cells and binding to androgen receptors that act as molecular switches. These switches trigger changes in cell behavior: muscle cells build more protein, bone cells maintain bone structure, brain cells influence mood and cognitive function, and cells in the reproductive system support sexual function.

Your body also converts some of the absorbed testosterone into two other important hormones. An enzyme called 5-alpha reductase converts testosterone into dihydrotestosterone (DHT), a more potent androgen that affects hair, skin, and prostate tissue. Another enzyme, aromatase, converts some testosterone into estradiol, a form of estrogen that men need for bone health, brain function, and cardiovascular protection. One notable feature of the patch is that it produces lower DHT levels compared to testosterone gels, because gels pass through skin that contains more 5-alpha reductase enzyme. This difference may be relevant for men concerned about DHT-related effects like hair thinning.

The Science

Androderm delivers unesterified testosterone transdermally, with the stratum corneum serving as the rate-limiting barrier and reservoir for sustained release into the dermal microcirculation. The permeation-enhanced design uses alcohol and other excipients to facilitate testosterone transport across the skin [1].

Free testosterone exerts biological effects through binding to the intracellular androgen receptor (AR), a member of the nuclear receptor superfamily. The classical genomic pathway involves ligand-AR binding, receptor dimerization, nuclear translocation, and interaction with androgen response elements (AREs) in target gene promoters, modulating transcription over hours to days. Non-genomic signaling through membrane-associated AR activates rapid second messenger cascades (MAPK/ERK, PI3K/Akt, intracellular calcium) within seconds to minutes [4].

Testosterone undergoes two primary metabolic conversions. 5-alpha reductase (types I and II) irreversibly converts testosterone to DHT, which has approximately 2-3 times greater AR binding affinity and mediates androgenic effects in skin, hair follicles, and prostate tissue. Aromatase (CYP19A1), expressed predominantly in adipose tissue, brain, and bone, converts testosterone to 17-beta-estradiol (E2) [4].

A pharmacologically significant observation from the Mazer (2005) crossover study is that DHT levels and DHT/T ratios were 2 to 3-fold higher with testosterone gel compared to the patch (P < 0.0001), while E2 levels and E2/T ratios were comparable between the two formulations. This difference reflects the higher concentration of 5-alpha reductase in skin compared to deeper tissues, resulting in greater first-pass DHT conversion when testosterone is delivered via gel applied over larger skin surface areas [5].

Exogenous testosterone administration suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, reducing GnRH pulse frequency and amplitude, which decreases LH and FSH secretion. This results in reduced intratesticular testosterone concentrations and impaired spermatogenesis, a critical consideration for men of reproductive age regardless of testosterone delivery method [6].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

Understanding how the Androderm patch moves testosterone through your body helps explain why application timing and technique matter. When you apply the patch in the evening, about 10-20% of the testosterone in the patch actually crosses through your skin and reaches your bloodstream. That percentage might sound low, but the patch is designed with this in mind: the 4 mg/day system contains 19.5 mg of testosterone, calibrated so the approximately 4 mg that gets absorbed produces testosterone levels within the normal range for most men.

What makes the patch pharmacologically distinctive is its timing. Because you apply it at night, testosterone levels rise through the early morning hours and reach their peak roughly 8 hours after application. This closely mirrors the natural pattern in healthy men, whose testosterone levels are highest in the early morning and gradually decline through the day. Gels, applied in the morning, produce a flatter profile without this natural rhythm. Injections produce sharp peaks followed by progressive decline.

After you remove the patch, your testosterone levels drop relatively quickly, returning to hypogonadal levels within about 24 hours. This is why consistent daily application is essential: there is no depot effect or buildup in your system. Each patch delivers one day's worth of testosterone.

One practical consideration: showering 3 hours after patch application has minimal effect on testosterone absorption (less than 1% change). The majority of absorption into the skin's reservoir occurs within the first few hours of application.

The Science

Absorption: Androderm delivers physiologic amounts of testosterone with continuous absorption during the 24-hour dosing period. Median Tmax is 8 hours (range 4-12 hours) post-application. The stratum corneum serves as the primary absorption barrier and reservoir [1].

Steady-state pharmacokinetics (Day 28 data from pivotal trial):

Comparative PK (Patch vs Gel, Mazer 2005 crossover study, n=28):

Circadian profile: Nightly patch application produces a mean total testosterone profile that mimics the circadian pattern of healthy men, with peak levels in the early morning hours. This is a unique pharmacokinetic advantage of the patch over gel (which produces a flatter profile) and injections (which produce supraphysiological peaks followed by decline) [5].

Distribution: Approximately 40% bound to SHBG, 2% free (unbound), remainder bound to albumin and other proteins [1].

Metabolism: Testosterone is metabolized to 17-keto steroids through two primary pathways. During steady-state with Androderm, the average DHT:T ratio is approximately 1:10 and the E2:T ratio is approximately 1:200, both within physiological range [1].

Elimination: Upon system removal, serum testosterone decreases with an apparent half-life of approximately 70 minutes. Hypogonadal concentrations are reached within 24 hours. There is no accumulation during continuous treatment. Approximately 90% of a dose is excreted in urine as glucuronic and sulfuric acid conjugates; approximately 6% in feces [1].

Showering effect: Showering 3 hours post-application increased Cavg by 0.5% and decreased Cmax by 0.4%, which is not clinically significant [1].

Research & Clinical Evidence

The Basics

The Androderm patch has been studied in clinical trials since the early 1990s, with the FDA granting approval in 1995 based on evidence that the non-scrotal transdermal system could reliably normalize testosterone levels in hypogonadal men. While Androderm-specific research is less extensive than that for testosterone gels or injectable formulations, several important studies inform its clinical profile.

The pivotal clinical trial enrolled 40 hypogonadal men (ages 34-76) who were switched to the new 4 mg/day formulation. After 28 days of treatment, 97% achieved average testosterone concentrations within the normal range (300-1030 ng/dL). This high success rate is notable because these men had previously been on other testosterone formulations.

Beyond Androderm-specific data, the broader body of TRT research applies to all testosterone delivery methods. The TRAVERSE trial (2023), the largest randomized controlled trial designed to assess cardiovascular safety of TRT, enrolled 5,246 men aged 45-80 with hypogonadism and cardiovascular risk factors. The trial used testosterone gel, not patches, but its findings on cardiovascular safety are relevant to all testosterone formulations.

The Science

Pivotal Androderm trial (n=40, current formulation): 38/40 subjects were white, 25% Hispanic, mean age 55 years. Subjects previously stable on other topical testosterone products were switched to Androderm 4 mg/day. After titration at Day 15 (based on Day 8 testosterone levels), 86% remained at 4 mg/day, 11% titrated to 2 mg/day, 3% titrated to 6 mg/day. At Day 28, 34/35 completers (97%) achieved Cavg within normal range [1].

Older formulation studies (n=94, ages 15-65): Using the 2.5/5/7.5 mg/day systems, 92% of patients achieved morning serum testosterone within the normal reference range. 93% of patients used the 5 mg daily dose [1].

Mazer crossover study (n=28): Demonstrated bioequivalence of patch and gel for total testosterone Cavg and Cmax, with the patch uniquely mimicking circadian testosterone patterns. Showed 2-3x lower DHT/T ratios with patch vs gel [5].

Bhasin HIV study (n=41, RCT with placebo): Androderm in HIV-infected hypogonadal men showed 1.35 kg lean body mass gain, greater fat mass reduction vs placebo, increased red cell count, and improvement in emotional functioning. Testosterone replacement was safe in this population over 12 weeks [7].

De Sanctis thalassemia study (n=9, 12 months): Demonstrated that Androderm produced physiologically appropriate testosterone levels, lowered SHBG, promoted growth and virilization, and increased bone mineral density in hypogonadal adolescents and young men with beta-thalassemia major [8].

TRAVERSE trial (n=5,246, testosterone gel vs placebo) [9]: Although not Androderm-specific, TRAVERSE is the definitive cardiovascular safety study for TRT. In men aged 45-80 with hypogonadism and preexisting or high risk for cardiovascular disease, testosterone gel demonstrated non-inferiority for the primary composite MACE endpoint (death from cardiovascular causes, nonfatal MI, nonfatal stroke) with HR 0.96 (95% CI: 0.78-1.17) over mean 33-month follow-up. The upper bound of the 95% CI (1.17) was below the prespecified non-inferiority margin of 1.20. TRAVERSE also noted increased incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group [9].

Evidence & Effectiveness Matrix

Categories scored: 18
Categories with community data: 10
Categories not scored (insufficient community data): Cognitive Function, Bone Health, Cardiovascular Health, Metabolic Health, Sleep Quality, Gynecomastia & Estrogen, Fluid Retention & Edema, Prostate Health

Benefits & Therapeutic Effects

The Basics

For men with diagnosed hypogonadism, Androderm can restore testosterone levels to the normal range and produce meaningful improvements across several areas of health. The benefits most consistently reported by users and supported by clinical evidence include improved energy levels, restored sexual function and libido, mood stabilization, and gradual improvements in body composition.

What distinguishes the patch from other testosterone delivery methods is not a difference in what testosterone does once it reaches your bloodstream, but in how it gets there. The patch's unique advantages include the circadian rhythm it produces (mimicking natural testosterone patterns), the absence of transfer risk to partners or children (a significant concern with gels), and the elimination of needles. These practical advantages can improve adherence and quality of life for men who find injections difficult or gel application impractical.

The most commonly reported early benefit is improvement in sexual function and libido, often noticed within the first few weeks. Energy improvement typically follows. Mood stabilization, body composition changes, and bone density improvements take longer, with meaningful changes often requiring 3-6 months of consistent use.

The Science

Clinical evidence supports the following therapeutic effects of testosterone replacement via Androderm:

Sexual function: Testosterone replacement consistently improves libido, erectile function, and sexual satisfaction in hypogonadal men. The TTrials sexual function substudy demonstrated significant improvement in sexual activity and desire with testosterone vs placebo [10].

Body composition: The Bhasin HIV study demonstrated a 1.35 kg gain in lean body mass and greater fat mass reduction vs placebo over 12 weeks with Androderm [7]. These effects are consistent with the broader TRT body composition literature.

Bone mineral density: The De Sanctis thalassemia study showed increased BMD with 12 months of Androderm treatment [8]. The TTrials bone substudy demonstrated significant increases in volumetric BMD and estimated bone strength with testosterone vs placebo [11].

Hematologic effects: Androderm increases red cell count, which is generally a therapeutic effect in hypogonadal men (who often have mild anemia) but requires monitoring to avoid polycythemia [7].

Unique PK advantage: The circadian testosterone profile produced by the patch may have theoretical benefits for sleep architecture and morning energy, as it aligns exogenous testosterone delivery with the body's natural hormonal rhythm. However, no head-to-head outcome studies have compared clinical outcomes between circadian and non-circadian testosterone delivery patterns [5].

Risks, Side Effects & Safety

The Basics

Like all forms of testosterone replacement therapy, Androderm carries real risks that require ongoing monitoring and honest discussion with your healthcare provider. The most important thing to understand about TRT risks is that they are manageable when properly monitored, and they vary by delivery method, dose, and individual health factors.

The most common side effect specific to the Androderm patch is skin irritation at the application site. In clinical trials, 28% of patients using the newer formulation experienced some form of application site reaction, and up to 48% with the older formulation. This ranges from mild redness to blistering and contact dermatitis. For many users, this is the factor that ultimately determines whether they continue with patches or switch to another delivery method. Applying a small amount of 0.1% triamcinolone acetonide cream under the patch has been shown to reduce irritation without significantly affecting testosterone absorption.

Beyond skin irritation, the risks of Androderm are similar to those of all testosterone formulations, though some risks may be modestly lower with transdermal delivery compared to injections.

The Science

Common side effects (from Androderm clinical trials [1]):

Serious risks with absolute risk context:

Cardiovascular events (MACE): The TRAVERSE trial (n=5,246, testosterone gel vs placebo, men aged 45-80 with CV risk factors) found no significant increase in MACE with testosterone vs placebo: HR 0.96 (95% CI: 0.78-1.17) over 33 months. In absolute terms, MACE occurred in 7.0% of the testosterone group vs 7.3% of the placebo group. However, TRAVERSE noted increased rates of atrial fibrillation (HR 1.27), pulmonary embolism (HR 1.92), and acute kidney injury (HR 1.69) in the testosterone group. Earlier observational studies and meta-analyses produced conflicting results, with some suggesting increased risk in the first 90 days. The Androderm label (revised 2016, prior to TRAVERSE) states that epidemiologic studies and RCTs are "inconclusive" for MACE risk [1][9].

Polycythemia/erythrocytosis: Testosterone stimulates erythropoiesis. Hematocrit above 54% requires dose reduction, route change, or therapeutic phlebotomy. Transdermal delivery (patches and gels) generally produces lower polycythemia rates than intramuscular injections, likely due to lower peak testosterone concentrations and more stable levels. The Androderm label requires hematocrit monitoring prior to treatment, at 3-6 months, and annually thereafter [1][12].

Prostate effects: Prostate abnormalities were reported in 5% of patients in the older Androderm clinical trials. PSA monitoring is required. Current evidence does not support a causal link between physiological-range TRT and prostate cancer initiation (the "saturation model" suggests prostate tissue is maximally stimulated at relatively low androgen concentrations). However, active prostate cancer remains an absolute contraindication [1][13].

Fertility suppression: Exogenous testosterone, regardless of delivery method, suppresses the HPG axis and may cause azoospermia. The Androderm label states: "At large doses of exogenous androgens, spermatogenesis may be suppressed through feedback inhibition of pituitary FSH." See Section Section 13 for full coverage [1].

Sleep apnea: May potentiate OSA in patients with risk factors (obesity, chronic lung disease). Screening before initiation is recommended [1].

Gynecomastia: May develop and persist. Aromatization of testosterone to estradiol occurs with all delivery methods [1].

Hepatotoxicity: Not associated with Androderm. This risk is specific to 17-alpha-alkylated oral androgens (historical formulations). The label explicitly states: "ANDRODERM is not known to cause these adverse effects" [1].

MRI burns: Androderm contains aluminum in its disc layer. Skin burns have been reported when the patch is worn during MRI. The patch must be removed before MRI [1].

Risk modifiers: Individual risk is influenced by obesity (higher aromatization, higher polycythemia risk), sleep apnea (may worsen), cardiovascular disease (requires careful risk-benefit analysis), age (older men may have higher polycythemia and prostate risk), and dose (higher doses increase side effects).

Contraindications:

• Absolute: Known or suspected prostate cancer, male breast cancer, women who are or may become pregnant
• Relative: Hematocrit >54% at baseline, uncontrolled heart failure, untreated severe OSA, desire for near-term fertility

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're noticing acne, water retention, mood changes, or any other shift, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also tracks your hematocrit and PSA values over time, alerting you when levels approach thresholds that need attention.

Dosing & Treatment Protocols

The Basics

Androderm dosing follows a straightforward approach: start with one 4 mg/day patch applied each evening, then check testosterone levels after two weeks to see if the dose needs adjustment. Your provider will draw blood early in the morning (after you've worn the patch overnight) to measure your testosterone level at its peak. The target range is 400-930 ng/dL.

If your levels are below 400 ng/dL, your provider may increase your dose to 6 mg/day (one 4 mg patch plus one 2 mg patch). If your levels are above 930 ng/dL, the dose may be reduced to 2 mg/day. In the pivotal clinical trial, 86% of patients did well on the starting dose of 4 mg/day without needing any adjustment.

The patch is applied in the evening and worn for 24 hours. You replace it with a fresh patch the following evening, applying to a different site. You must rotate application sites and wait at least 7 days before reusing the same spot. This rotation is essential for managing skin irritation.

The Science

Protocol summary [1]:

Clinical trial titration results (n=36) [1]:

• 86% (31/36) remained on 4 mg/day
• 11% (4/36) titrated down to 2 mg/day
• 3% (1/36) titrated up to 6 mg/day

Dose conversion from older formulations:

• 2.5 mg/day (old) to 2 mg/day (new)
• 5.0 mg/day (old) to 4 mg/day (new)
• 7.5 mg/day (old) to 6 mg/day (new)

Getting the dosing right often takes time and fine-tuning with your provider. Keeping an accurate record of your patch applications, doses, and any adjustments makes that process smoother. Doserly tracks your testosterone doses alongside everything else in your health stack, so your full protocol is always in one place.

Never wonder whether you applied your patch or when your last application was. The app logs every dose with a timestamp and sends reminders when your next one is due, helping you maintain the consistency that makes testosterone therapy most effective and keeps your levels stable.

What to Expect (Timeline)

Days 1-7: Possible initial energy or mood lift (partly placebo). Skin irritation at application site is common from the first application. Mild redness is normal and expected. Some users report rapid onset of libido changes. Getting accustomed to wearing a patch (adhesion, comfort, site selection).

Weeks 2-4: First blood draw for dose titration (early morning, 2 weeks after starting). Libido improvements often the first noticeable sustained effect. Energy improvements may become apparent. Skin irritation pattern will become clearer; some men tolerate well, others develop progressive reactions.

Months 1-3: Sexual function improvements consolidate. Initial body composition changes may begin. Mood stabilization. Hematocrit beginning to rise (check at 3-6 months). Skin tolerance established or worsening; this is the critical window where many users decide whether to continue with patches.

Months 3-6: Body composition changes become more visible (fat loss, modest lean mass gains). Strength improvements. Bone density changes beginning. Full benefit of mood and energy improvements.

Months 6-12: Full sexual function benefits. Significant body composition changes. Bone density measurable improvements (if indicated). Some honeymoon-phase effects may normalize to a new, stable baseline.

Ongoing maintenance: Annual review with provider. Dose reassessment based on symptoms and labs. Continued monitoring (hematocrit, PSA, lipids). Ongoing site rotation and skin health management.

Realistic expectations: Individual response varies widely. Not all symptoms may resolve with TRT alone, especially if the underlying cause is not purely hormonal. Body composition changes with transdermal delivery may be more modest than with intramuscular injections due to lower peak testosterone levels. Dose adjustment is common.

Fertility Preservation & HPG Axis

Exogenous testosterone, regardless of whether it is delivered via patch, gel, injection, or any other method, suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This is a fundamental pharmacological effect that cannot be avoided. When testosterone enters your body from an external source, your brain detects adequate hormone levels and reduces the signals (GnRH, LH, FSH) that tell your testes to produce testosterone and maintain sperm production.

HPG axis suppression timeline: Sperm count typically begins declining within 2-3 months of starting TRT. Approximately 40-60% of men on TRT achieve azoospermia (zero sperm count) by 6 months, with most others showing severe oligospermia (very low sperm count) [6].

HCG co-administration: Some providers prescribe human chorionic gonadotropin (HCG) at 250-500 IU 2-3 times weekly alongside testosterone to maintain intratesticular testosterone levels and preserve some degree of spermatogenesis. This approach has evidence supporting its use but is not universally recommended and adds complexity and cost to the protocol.

Alternatives for fertility-seeking men: For men who need testosterone support but want to maintain fertility, selective estrogen receptor modulators (SERMs) such as clomiphene citrate (25-50 mg daily) or enclomiphene can raise endogenous testosterone by stimulating LH and FSH production without suppressing spermatogenesis. These are used off-label for male hypogonadism [14].

Sperm banking: Men of reproductive age who are starting any form of TRT, including Androderm, should be counseled about sperm banking before treatment initiation if they desire biological children in the future.

Recovery after discontinuation: If TRT is stopped, HPG axis recovery is variable and not guaranteed. Recovery timelines range from 6 to 24+ months. Factors affecting recovery include duration of TRT use (longer use is associated with slower recovery), age, pre-TRT hormonal status, and whether HCG was used during TRT. Men with primary hypogonadism (testicular failure) have more limited recovery potential than those with secondary hypogonadism (pituitary/hypothalamic dysfunction) [15].

Clinical importance: Fertility counseling should be part of every TRT initiation conversation for men of reproductive age. This is not a minor side effect. The Androderm label states: "At large doses of exogenous androgens, spermatogenesis may be suppressed through feedback inhibition of pituitary FSH that could lead to adverse effects on semen parameters including reduction of sperm count" [1].

Interactions & Compatibility

Drug-drug interactions:

• Anticoagulants (warfarin, dicumarol, phenprocoumon): Testosterone may enhance anticoagulant effect. More frequent INR monitoring recommended at initiation and termination of TRT [1].
• Insulin and diabetes medications: Testosterone may improve insulin sensitivity and decrease blood glucose, potentially requiring insulin dose reduction [1].
• Corticosteroids/ACTH: Concurrent use may increase fluid retention. Monitor in patients with cardiac, renal, or hepatic disease [1].
• 5-alpha reductase inhibitors (finasteride, dutasteride): Block DHT conversion. May affect efficacy and side effect profile of TRT. Cross-reference: Estrogen Management on TRT.
• Bupropion, methotrexate, paclitaxel, levoketoconazole: Listed as interactions requiring caution by Drugs.com [16].
• Triamcinolone: Ointment formulation significantly reduces testosterone absorption from Androderm. However, 0.1% cream applied under the central reservoir does not significantly affect absorption and can be used to manage skin irritation [1].

Supplement interactions:

• DHEA: Additive androgenic effects; may increase total androgen load
• Boron: May increase free testosterone by reducing SHBG
• Zinc: Supports testosterone production; supplementation in zinc-deficient men may modestly increase T levels
• Saw palmetto: 5-alpha reductase inhibition; may interact with DHT-mediated effects

Lifestyle factors:

• Alcohol: Suppresses testosterone production and increases aromatization
• Sleep: Critical for testosterone production; TRT may worsen obstructive sleep apnea
• Exercise: Resistance training is synergistic with TRT for body composition
• Body composition: Weight loss alone may normalize testosterone in obese men, potentially reducing or eliminating the need for TRT

Cross-references:

• Testosterone Gel (AndroGel)
• Testosterone Gel (Testim)
• Testosterone Cypionate
• Compounded Testosterone Cream

Decision-Making Framework

The decision to start TRT, and specifically to use a transdermal patch, involves multiple considerations. Current Endocrine Society guidelines require two morning total testosterone measurements below the lower limit of normal (typically below 264-300 ng/dL, depending on the laboratory) plus the presence of symptoms before diagnosing hypogonadism. The AUA uses a 300 ng/dL threshold; the EAU uses 12.1 nmol/L (approximately 350 ng/dL).

When the patch may be a particularly good fit:

• Men who want to avoid needles entirely
• Men with partners or children at home (no transfer risk, unlike gels)
• Men who value consistent, circadian-pattern testosterone delivery
• Men who prefer a fixed-dose, "set and forget" daily application
• Men concerned about DHT-related effects (patches produce lower DHT than gels)

When the patch may not be ideal:

• Men with sensitive skin or history of contact dermatitis
• Men who are very physically active or sweat heavily (patch adhesion issues)
• Men who prefer the flexibility of dose adjustment available with gels
• Men for whom cost is a primary concern (patches are generally more expensive than generic injectables)

Questions to ask your provider: Has the diagnosis of hypogonadism been confirmed with two morning testosterone levels? Have reversible causes been evaluated (obesity, sleep apnea, opioid use, pituitary pathology)? What monitoring schedule will be used? How will fertility be addressed? What is the expected cost with your insurance?

Administration & Practical Guide

Patch application step-by-step:

1. Apply in the evening, approximately the same time each night
2. Select a clean, dry, non-hairy area on the back, abdomen, upper arms, or thighs
3. Avoid bony prominences, areas under pressure during sleep, oily or damaged skin
4. Do NOT apply to the scrotum
5. Open the foil pouch and remove the patch immediately
6. Peel off the protective liner and silver disc
7. Check that no adhesive remains on the liner; discard patch if adhesive transferred
8. Apply immediately with sticky side down, pressing firmly around edges
9. Wash hands after application

Site rotation: Rotate application sites daily. Do not reuse the same site for at least 7 days. Keeping a log of which sites you've used prevents accidental reuse and helps manage skin irritation.

Managing skin irritation:

• Apply 0.1% triamcinolone acetonide cream under the central reservoir area before patch application (clinically proven to reduce irritation without affecting absorption)
• After patch removal, OTC hydrocortisone cream may help with residual redness
• Some users report success with alcohol prep pads before application (improves adhesion)
• Avoid applying to skin that is still warm from a shower

If the patch falls off:

• Before noon: apply a new patch, then replace as usual in the evening
• After noon (worn >12 hours): wait until regular evening application time
• Do not tape the patch to skin

Showering/swimming: Wait at least 3 hours after application. Showering after 3 hours does not significantly affect absorption. Heavy exercise and sweating may loosen the patch.

MRI safety: Remove the patch before any MRI procedure. The aluminum component can cause skin burns during MRI [1].

Knowing how to apply your patch correctly is the first step. Remembering to actually apply it on schedule, every evening, is what keeps your levels stable. Doserly sends smart reminders tailored to your specific protocol, whether that is a nightly patch application, a twice-weekly injection, or a daily gel routine.

The app adapts to your routine, not the other way around. Set reminders that work with your schedule, track application site rotation to manage skin irritation, and confirm each application with a tap. Consistency is one of the most important factors in TRT effectiveness, and the app helps you maintain it without mental overhead.

Monitoring & Lab Work

Pre-TRT baseline labs:

• Total testosterone (two morning draws on separate days)
• Free testosterone (calculated or equilibrium dialysis)
• LH, FSH (distinguish primary vs secondary hypogonadism)
• Estradiol, SHBG
• CBC with hematocrit (baseline for polycythemia monitoring)
• PSA (age-appropriate baseline)
• Lipid panel
• Comprehensive metabolic panel
• DEXA if osteoporosis risk factors present

Initial follow-up (2-4 weeks):

• Early morning serum testosterone (measure following nightly patch application)
• Target: 400-930 ng/dL
• Dose adjustment if outside range

Follow-up at 3-6 months:

• Hematocrit (threshold >54% for intervention)
• PSA
• Testosterone levels (reassess if symptoms not improving)
• Side effect evaluation
• Symptom assessment

Ongoing monitoring schedule:

• Hematocrit: every 6-12 months
• PSA: per age-appropriate screening guidelines, annually for men over 40
• Testosterone levels: as clinically indicated
• Estradiol: only if symptomatic (gynecomastia, fluid retention)
• Lipid panel: annually
• Bone density (DEXA): if osteoporosis was an indication
• Semen analysis: if fertility is a concern

Annual review checklist: Symptom reassessment, continued indication, risk-benefit discussion, dose optimization, skin tolerance assessment.

Estrogen Management on TRT

Testosterone is converted to estradiol by the aromatase enzyme, primarily in adipose tissue. This is a normal and necessary physiological process. Men need estradiol for bone health, cardiovascular protection, cognitive function, and libido. The goal is not to eliminate estrogen but to maintain it in appropriate proportion to testosterone.

Androderm produces physiological E2/T ratios (approximately 1:200) during steady-state treatment. The patch does not typically produce supraphysiological testosterone peaks, which means aromatization-driven estradiol spikes are less likely than with intramuscular injections.

Aromatase inhibitor use: Routine AI use is not recommended by Endocrine Society or AUA guidelines. Anastrozole should only be considered if clinical symptoms of elevated estrogen are present (gynecomastia, significant fluid retention, emotional lability) and confirmed by laboratory findings. Excessive E2 suppression causes joint pain, mood disturbance, decreased libido, and bone density loss.

Community context: The online men's health community places heavy emphasis on estrogen management and often targets specific E2 ranges (20-35 pg/mL). Clinical guidelines do not support number-chasing and recommend symptom-based management only.

Cross-reference: Estrogen Management on TRT, Anastrozole (Arimidex)

Stopping TRT / Post-Cycle Considerations

HPG axis recovery: When exogenous testosterone is discontinued, LH and FSH remain suppressed for weeks to months. Endogenous testosterone production may take 6-24+ months to recover, and recovery to pre-TRT levels is not guaranteed.

PCT protocols (community-derived, limited formal study):

• HCG taper: 1000-2000 IU every other day for 2-4 weeks, then taper
• Clomiphene citrate: 25-50 mg daily for 4-8 weeks to stimulate LH/FSH recovery
• Enclomiphene: newer SERM, may have fewer side effects
• These protocols are not standardized in clinical guidelines for TRT discontinuation

Primary vs secondary hypogonadism: Men with primary hypogonadism (testicular failure) have limited recovery potential regardless of PCT. Men with secondary hypogonadism (pituitary/hypothalamic) generally have better prognosis for axis recovery.

Is TRT lifelong? For many men with classical hypogonadism, yes. For secondary hypogonadism, addressing underlying causes (weight loss, sleep apnea treatment, opioid cessation) may restore endogenous production. For age-related decline, the answer is individualized.

Realistic expectations: Not everyone recovers fully. Some men return to pre-TRT levels, some recover partially, some do not recover meaningfully. This should be discussed before starting TRT.

Cross-reference: Stopping TRT & Post-Cycle Recovery

Special Populations & Situations

Obese Men

Weight loss alone may normalize testosterone levels. Consider lifestyle intervention first. If TRT is initiated in obese men, higher aromatization rates may lead to elevated estradiol. The transdermal patch may have variable absorption in men with thick subcutaneous fat layers.

Men with Sleep Apnea

TRT may exacerbate obstructive sleep apnea. CPAP optimization before and during TRT is recommended. Sleep study should be considered before initiation, especially in at-risk patients.

Men with Prostate Cancer History

Historically an absolute contraindication. Evolving evidence suggests the saturation model may apply (exogenous T at physiological levels may not further stimulate prostate). Requires specialized urological consultation. Active prostate cancer remains contraindicated.

Cardiovascular Disease History

TRAVERSE provides reassurance for non-inferiority in the MACE composite endpoint. Transdermal delivery may be preferred over IM injections for men with cardiovascular risk, as it produces more stable levels and lower polycythemia rates. Hematocrit monitoring is critical.

Type 2 Diabetes

TRT may improve insulin sensitivity, HbA1c, and metabolic parameters in hypogonadal diabetic men. The Androderm label notes that androgens may decrease blood glucose and insulin requirements; dose adjustment of diabetes medications may be needed.

Older Men (>65)

Age-related decline vs true hypogonadism must be distinguished. Lower starting doses are often appropriate. Increased polycythemia risk with age. Prostate monitoring should be heightened. TRAVERSE and TTrials data primarily come from this population.

Transgender Men (FTM)

Different dosing goals (masculinizing doses). Patches are sometimes used when injection needle phobia is present. Fertility counseling is essential (oocyte preservation). Community data from FTM users provides significant real-world Androderm experience data, as patches have been relatively more commonly used in this population compared to cisgender TRT.

Regulatory, Insurance & International

United States (FDA/DEA):

• NDA020489, approved September 29, 1995
• Schedule III controlled substance (CIII)
• FDA-approved for classical hypogonadism only (NOT age-related decline)
• Available strengths: 2 mg/day and 4 mg/day systems
• Cost: approximately $440-650/month without insurance; savings programs available
• Insurance coverage varies; prior authorization often required
• Generic not widely available

Canada:

• Marketed as Androplex

International availability:

• Availability varies by country. Transdermal patches are less widely available internationally than gels or injectable formulations.

Travel considerations:

• Schedule III controlled substance; carry a copy of your prescription when traveling
• Some countries have additional restrictions on testosterone importation

Frequently Asked Questions

Q: How quickly does the Androderm patch start working?
A: Testosterone levels begin rising within hours of the first application, with peak levels typically reached about 8 hours later. Some men notice changes in libido or energy within the first week, though this may partly reflect placebo expectation. Meaningful, sustained benefits typically develop over weeks to months. Body composition changes may take 3-6 months.

Q: Why does the patch cause skin irritation?
A: The transdermal delivery system uses a permeation enhancer to help testosterone cross the skin barrier. This enhancer can irritate the skin in a significant percentage of users (28-48% in clinical trials). The irritation is not always an allergic reaction; it is often a direct effect of the delivery mechanism. Applying 0.1% triamcinolone acetonide cream under the patch can reduce this irritation.

Q: Can I apply the patch to my scrotum?
A: No. Androderm must NOT be applied to the scrotum. Earlier testosterone patch products were designed for scrotal application, but Androderm is specifically formulated for non-scrotal skin.

Q: What should I do if the patch falls off?
A: If it falls off before noon, apply a new patch and replace as usual in the evening. If it falls off after noon (worn more than 12 hours), wait until your regular evening application time. Do not tape the patch to your skin.

Q: Can I shower or swim with the patch on?
A: Yes, but wait at least 3 hours after application. Showering after 3 hours has minimal effect on testosterone absorption (less than 1% change). Heavy exercise and sweating may loosen the patch.

Q: Is Androderm the same as testosterone gel?
A: No. While both are transdermal, they have different pharmacokinetic profiles. The patch mimics the natural circadian rhythm of testosterone when applied at night, while gels produce a flatter profile. Patches also produce lower DHT levels (2-3x lower DHT/T ratio than gels) and carry no risk of interpersonal transfer.

Q: Will Androderm affect my fertility?
A: Yes. All forms of exogenous testosterone suppress the HPG axis and can reduce or eliminate sperm production. If you want biological children in the future, discuss fertility preservation options (sperm banking, HCG, SERMs) with your provider before starting any testosterone therapy.

Q: Do I need to remove the patch for an MRI?
A: Yes, absolutely. Androderm contains aluminum, which can cause skin burns during MRI. Always remove the patch before any MRI procedure.

Q: Why is the patch more expensive than injections?
A: Transdermal patch technology is more complex to manufacture than injectable testosterone solutions. Generic injectable testosterone cypionate costs $30-50/month, while Androderm can cost $440-650/month without insurance. Savings programs and manufacturer coupons may reduce out-of-pocket costs.

Q: Should I start TRT?
A: This is a decision that requires clinical evaluation by a qualified healthcare provider. TRT is appropriate for men with confirmed hypogonadism (two low morning testosterone levels plus symptoms) after reversible causes have been evaluated. The choice between patch, gel, and injection depends on individual factors including lifestyle, cost, skin sensitivity, and personal preference.

Myth vs. Fact

Myth: TRT causes heart attacks.
Fact: The TRAVERSE trial (n=5,246), the largest RCT designed to assess cardiovascular safety of TRT, found no significant increase in major adverse cardiovascular events with testosterone vs placebo (HR 0.96, 95% CI: 0.78-1.17) over 33 months. In absolute terms, MACE occurred in 7.0% of the testosterone group vs 7.3% of the placebo group. However, TRAVERSE did note increased rates of atrial fibrillation and pulmonary embolism, so cardiovascular monitoring remains important [9].

Myth: TRT causes prostate cancer.
Fact: Current evidence does not support a causal link between testosterone replacement at physiological levels and prostate cancer initiation. The "saturation model" suggests that prostate tissue is maximally stimulated at relatively low androgen concentrations. PSA monitoring is standard practice, and active prostate cancer remains a contraindication [13].

Myth: TRT is just steroids.
Fact: TRT replaces testosterone to normal physiological levels (typically targeting 400-700 ng/dL). This is fundamentally different from anabolic steroid abuse, which uses supraphysiological doses (300-1000+ mg/week) to achieve performance enhancement. Androderm delivers approximately 4 mg/day, designed to mimic normal physiological production.

Myth: Once you start TRT, you can never stop.
Fact: Many men can stop TRT and recover endogenous testosterone production, though recovery is not guaranteed and may take 6-24+ months. Recovery depends on the underlying cause of hypogonadism, duration of TRT use, age, and whether the HPG axis retains functional capacity. Men with primary hypogonadism (testicular failure) may have limited recovery [15].

Myth: TRT will make you permanently infertile.
Fact: TRT suppresses spermatogenesis, often to azoospermia. However, this is usually reversible after discontinuation, with recovery occurring over months to years. Sperm banking before TRT initiation is recommended for men who may want biological children. HCG co-administration during TRT may help preserve fertility [6].

Myth: All men over 40 need TRT.
Fact: Age-related testosterone decline is normal and does not automatically indicate hypogonadism. The FDA has not established safety and efficacy of testosterone products for age-related decline. Lifestyle factors (weight management, exercise, sleep, stress reduction) should be optimized before considering TRT.

Myth: Higher testosterone doses are always better.
Fact: TRT aims for the therapeutic range, not maximum levels. Higher doses increase side effects (polycythemia, acne, sleep apnea, mood changes) without proportional benefit. The Androderm target range of 400-930 ng/dL reflects this principle.

Myth: Patches don't work as well as injections.
Fact: The patch achieves average testosterone concentrations bioequivalent to gel and produces levels within the normal range in 92-97% of users. However, peak levels may be lower than post-injection peaks, which can produce a subjective difference in how some men feel. Body composition effects may be more modest with transdermal delivery [5].

Sources & References

Clinical Guidelines

[1] Androderm (testosterone transdermal system) prescribing information. Actavis Pharma, Inc. DailyMed/NLM. NDA020489. Revised 10/2016.

[4] Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987;8(1):1-28.

[12] Endocrine Society. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

[13] American Urological Association. Evaluation and management of testosterone deficiency. AUA Guideline. 2018 (amended 2023).

Landmark Trials

[9] Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. (TRAVERSE trial)

[10] Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. (TTrials)

[11] Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471-479.

Pharmacokinetic Studies

[2] Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 1992;74(3):623-628.

[3] Mazer NA, Heiber WE, Moellmer JF, et al. Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men. J Control Release. 1992;19(1-3):347-361.

[5] Mazer NA. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J Sex Med. 2005;2(2):213-226.

Clinical Studies

[7] Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998;83(9):3155-3162.

[8] De Sanctis V, Vullo C, Urso L, et al. Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. J Pediatr Endocrinol Metab. 1998;11(6):891-900.

Regulatory and Institutional Sources

[6] U.S. Food and Drug Administration. Testosterone products: drug safety communication — FDA cautions about using testosterone products for low testosterone due to aging. 2015.

[14] Guay AT, Jacobson J, Perez JB, et al. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction. Int J Impot Res. 2003;15(3):156-165.

[15] Kohn TP, Louis MR, Pickett SM, et al. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil Steril. 2017;107(2):351-357.e1.

Drug Information Sources

[16] Drugs.com. Androderm prescribing information and consumer drug information. Accessed March 2026.

Related Guides & Cross-Links

Same Category (Transdermal Testosterone)

• Testosterone Gel (AndroGel)
• Testosterone Gel (Testim)
• Testosterone Gel (Fortesta)
• Compounded Testosterone Cream

Related Treatment Options (Injectable Testosterone)

• Testosterone Cypionate (Depo-Testosterone)
• Testosterone Enanthate (Delatestryl)
• Testosterone Undecanoate Injectable (Aveed / Nebido)

Ancillary Medications

• Anastrozole (Arimidex)
• HCG
• Clomiphene Citrate (Clomid)
• Enclomiphene Citrate

Treatment Overviews

• Testosterone Gels & Topicals Guide
• TRT for Beginners
• TRT Blood Work Guide
• Fertility Preservation on TRT
• Estrogen Management on TRT
• Stopping TRT & Post-Cycle Recovery

Conditions

• Primary Hypogonadism
• Secondary Hypogonadism
• Late-Onset Hypogonadism (Age-Related)